Adding Personalized mRNA Cancer Vaccine to Immunotherapy May Prolong Recurrence-Free Survival in Patients with High-Risk Melanoma; Clinical Benefit Was Independent of Patients’ Tumor Mutational Burden; Results Presented at AACR 2023 Termed “Extremely Important”

mRNA-4157/V940, a personalized mRNA-based cancer vaccine, in combination with
the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS)compared with pembrolizumab alone in patients with high-risk melanoma, and the clinical benefit was observed regardless of the tumor mutational burden (TMB) status, according to results from the phase IIb KEYNOTE-942 clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19 in Orlando, Florida.

Login Or Register To Read Full Story